111 related articles for article (PubMed ID: 34261667)
41. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
42. Cryopreservation of equine mononuclear cells for immunological studies.
Truax RE; Powell MD; Montelaro RC; Issel CJ; Newman MJ
Vet Immunol Immunopathol; 1990 Jun; 25(2):139-53. PubMed ID: 2378055
[TBL] [Abstract][Full Text] [Related]
43. A field-applicable method for flow cytometric analysis of granulocyte activation: Cryopreservation of fixed granulocytes.
de Ruiter K; van Staveren S; Hilvering B; Knol E; Vrisekoop N; Koenderman L; Yazdanbakhsh M
Cytometry A; 2018 May; 93(5):540-547. PubMed ID: 29533506
[TBL] [Abstract][Full Text] [Related]
44. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive evaluation of the effects of long-term cryopreservation on peripheral blood mononuclear cells using flow cytometry.
Li B; Yang C; Jia G; Liu Y; Wang N; Yang F; Su R; Shang Y; Han Y
BMC Immunol; 2022 Jun; 23(1):30. PubMed ID: 35672664
[TBL] [Abstract][Full Text] [Related]
46. In-Depth Immune-Oncology Studies of the Tumor Microenvironment in a Humanized Melanoma Mouse Model.
Schupp J; Christians A; Zimmer N; Gleue L; Jonuleit H; Helm M; Tuettenberg A
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33498319
[TBL] [Abstract][Full Text] [Related]
47. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
48. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
Hu HM; Winter H; Urba WJ; Fox BA
J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
[TBL] [Abstract][Full Text] [Related]
49. A Practical Cryopreservation and Staining Protocol for Immunophenotyping in Population Studies.
Barcelo H; Faul J; Crimmins E; Thyagarajan B
Curr Protoc Cytom; 2018 Apr; 84(1):e35. PubMed ID: 30040214
[TBL] [Abstract][Full Text] [Related]
50. A new procedure to analyze polymorphonuclear myeloid derived suppressor cells in cryopreserved samples cells by flow cytometry.
Sacchi A; Tumino N; Grassi G; Casetti R; Cimini E; Bordoni V; Ammassari A; Antinori A; Agrati C
PLoS One; 2018; 13(8):e0202920. PubMed ID: 30161175
[TBL] [Abstract][Full Text] [Related]
51. Comparison of Whole Blood Cryopreservation Methods for Extensive Flow Cytometry Immunophenotyping.
Serra V; Orrù V; Lai S; Lobina M; Steri M; Cucca F; Fiorillo E
Cells; 2022 May; 11(9):. PubMed ID: 35563832
[TBL] [Abstract][Full Text] [Related]
52. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
53. N-propionyl-4-S-cysteaminylphenol induces apoptosis in B16F1 cells and mediates tumor-specific T-cell immune responses in a mouse melanoma model.
Ishii-Osai Y; Yamashita T; Tamura Y; Sato N; Ito A; Honda H; Wakamatsu K; Ito S; Nakayama E; Okura M; Jimbow K
J Dermatol Sci; 2012 Jul; 67(1):51-60. PubMed ID: 22622238
[TBL] [Abstract][Full Text] [Related]
54. Stabilization of leukocytes from cerebrospinal fluid for central immunophenotypic evaluation in multicenter clinical trials.
Mexhitaj I; Lim N; Fernandez-Velasco JI; Zrzavy T; Harris KM; Muraro PA; Villar LM; Bar-Or A; Cooney LA
J Immunol Methods; 2022 Nov; 510():113344. PubMed ID: 36041516
[TBL] [Abstract][Full Text] [Related]
55. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
[TBL] [Abstract][Full Text] [Related]
56. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Suzuki E; Kapoor V; Jassar AS; Kaiser LR; Albelda SM
Clin Cancer Res; 2005 Sep; 11(18):6713-21. PubMed ID: 16166452
[TBL] [Abstract][Full Text] [Related]
57. HDAC9 deficiency promotes tumor progression by decreasing the CD8
Ning Y; Ding J; Sun X; Xie Y; Su M; Ma C; Pan J; Chen J; Jiang H; Qi C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554611
[TBL] [Abstract][Full Text] [Related]
58. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
59. Peptide vaccination directed against IDO1-expressing immune cells elicits CD8
Dey S; Sutanto-Ward E; Kopp KL; DuHadaway J; Mondal A; Ghaban D; Lecoq I; Zocca MB; Merlo LMF; Mandik-Nayak L; Andersen MH; Pedersen AW; Muller AJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32690770
[TBL] [Abstract][Full Text] [Related]
60. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. Assessment of critical cellular and molecular parameters.
Zatloukal K; Schneeberger A; Berger M; Schmidt W; Koszik F; Kutil R; Cotten M; Wagner E; Buschle M; Maass G
J Immunol; 1995 Apr; 154(7):3406-19. PubMed ID: 7897222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
